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Abstract: The current World Health Organization (WHO) classification system of primary brain tumors
is solely based on morphologic criteria. However,there is accumulating evidence that tumors with similar
histology have distinct molecular signatures that significantly impact treatment response and survival.
Recent practice-changing clinical trials have defined a role for routine assessment of MGMT promoter
methylation in glioblastoma patients,especially in the elderly,and 1p and 19q co-deletions in patients
with anaplastic glial tumors. Recently discovered molecular alterations including mutations in IDH-
1/2,EGFR,and BRAF also have the potential to become targets for future drug development. This
article aims to summarize current knowledge on the molecular biology of high grade gliomas relevant to
daily practice.
DOI: https://doi.org/10.5732/cjc.013.10218
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IDH WHO > I 
2° GBM 





No predictive role 









Not clearly defined 
WHO IV 
Vaccine or targeted therapies 
(experimental) 
1Almost all oligodendroglial tumors have LOH 1p/19q. 2Predicitve for the treatment 
with radiotherapy and/  or alkylating agents. 3Ependymoma and pilocytic astrocytoma  
do not have IDH mutation. 4EGFRvIII in ~33% of primary GBM. 
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2° GBM: secondary glioblastomas progress from low-grade diffuse astrocytoma or 
anaplastic astrocytoma. 1° GBM: 90% of glioblastomas develop rapidly de novo and 





Table 2. Glioma markers, overview of suitable methods for 









































IDH, isocitrate dehydrogenase; MGMT, O6-methylguanine methyltransferase; EGFR, 
epidermal growth factor receptor; IHC, immunohistochemistry; PCR, polymerase 
chain reaction; FISH, fluoresence in situ hybridization. 
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